Drugs / Ixekizumab
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | TALTZ | — | 2017-12-01 – 2022-05-04 | fda.gov ↗ |
| Approved | EU (EMA) | Taltz | — | 2016-04-25 | europa.eu ↗ |
| Approved | US (FDA) | TALTZ | — | 2016-03-22 | fda.gov ↗ |
Trials 58 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05030415 | Aug 2021 → Mar 2024 | lichen planopilaris, lichen planus | University of New Mexico | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT07200986 | Sep 2025 → Mar 2026 overdue | — | Celltrion | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04259346 | Feb 2020 → Feb 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03848403 | Jan → Jul 2019 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT03848416 | Jan → Jun 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03073213 | Apr 2017 → May 2019 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02993471 | Dec 2016 → Nov 2017 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02543918 | Sep → Nov 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01236118 | Dec 2010 → Jan 2013 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01253265 | May 2010 → Dec 2011 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT05309616 | Feb 2025 → May 2026 | idiopathic subglottic stenosis | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT04589325 | Nov 2022 → Feb 2027 expected | type 1 diabetes mellitus | Göteborg University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04979910 | Aug 2021 → Apr 2024 | major depressive disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT03485976 | May 2018 → Oct 2019 | pityriasis rubra pilaris | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT03099538 | Aug 2017 → Jun 2019 | bullous pemphigoid, pemphigoid | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03137160 | May 2017 → Aug 2018 | pyoderma gangrenosum | Ohio State University | Completed | No outcome recorded |
| Phase 2 | NCT01107457 | Apr 2010 → Jan 2011 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00966875 | Aug 2009 → Mar 2011 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06374979 | May → Jun 2025 | guttate psoriasis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT06588283 | Sep 2024 → Jan 2026 | obesity disorder, psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06588296 | Sep 2024 → Nov 2025 | obesity disorder, psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04527380 | Apr 2021 → Feb 2024 overdue | enthesitis-related juvenile idiopathic arthritis, psoriasis-related juvenile idiopathic arthritis | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04724629 | Jan → Mar 2021 | COVID-19 | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT04610476 | Oct 2020 → Oct 2024 | psoriatic arthritis, substance withdrawal syndrome | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT04285229 | Apr 2020 → Mar 2021 | spondyloarthropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03364309 | Apr 2018 → Jun 2020 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03129100 | May 2017 → May 2020 | spondyloarthropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03073200 | Mar 2017 → Feb 2019 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02757352 | Aug 2016 → Mar 2019 | spondyloarthropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02696785 | May 2016 → Dec 2017 | spondyloarthropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02696798 | Apr 2016 → May 2018 | spondyloarthropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02718898 | Apr 2016 → Feb 2017 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02634801 | Jan → Nov 2016 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02561806 | Oct 2015 → May 2016 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02584855 | Sep 2015 → Oct 2018 | psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02513550 | Aug 2015 → Nov 2016 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02387801 | Apr → Sep 2015 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02349295 | Dec 2014 → Sep 2016 | psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01870284 | Jul 2014 → Apr 2016 | ankylosing spondylitis | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 3 | NCT01777191 | Mar 2013 → May 2014 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01695239 | Dec 2012 → Dec 2014 | psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01646177 | Jul 2012 → May 2014 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01624233 | Jun 2012 → Sep 2013 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01597245 | May 2012 → Mar 2014 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01474512 | Nov 2011 → Jun 2014 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07149792 | Jul 2025 → Dec 2026 expected | psoriasis, psoriatic arthritis | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06398106 | Dec 2024 → Mar 2028 expected | psoriasis | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT05855967 | Jun 2023 → Aug 2024 | psoriasis, psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT06085079 | Jun 2022 → Dec 2024 | anterior uveitis, intermediate uveitis, panuveitis, posterior uveitis | Massachusetts Eye Research and Surgery Institution | Unknown | No outcome recorded |
| Phase 4 | NCT05080218 | Nov 2021 → Apr 2024 | psoriatic arthritis, spondyloarthropathy | Jeffrey Curtis | Completed | No outcome recorded |
| Phase 4 | NCT04537689 | Dec 2020 → Dec 2027 expected | psoriasis | Singapore General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04340076 | Aug 2020 → Jan 2025 | psoriasis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03942042 | Jul 2019 → Jul 2020 | generalized pustular psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT03573323 | Nov 2018 → Jul 2019 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT03151551 | Aug 2017 → Nov 2018 | psoriatic arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05503875 | Jan 2023 → Dec 2027 expected | psoriasis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06945107 Comparator | May 2025 → Jun 2026 overdue | psoriasis | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Active not recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07443956 Comparator | Mar 2026 → Feb 2028 expected | obesity disorder, psoriatic arthritis | NHS Greater Glasgow and Clyde | Recruiting | No outcome recorded |
| — | NCT06811558 Comparator | Feb → Dec 2025 overdue | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT05042635 Background | Oct 2021 → Sep 2024 | psoriasis | Shanghai Yueyang Integrated Medicine Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-06-13 | Incyte Corporation | Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017) incyte.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 71 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ixekizumab | “Ixekizumab (Taltz)” NCT07149792 ↗57 |
| Known as | IXE | “Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of patients with PsA and patients with...” PMID 37400681 ↗ Jul 20236“This study aimed to evaluate the outcomes of continuous versus interrupted ixekizumab (IXE) treatment and retreatment with IXE after disease worsening in Chinese patients.” PMID 39535685 ↗ Nov 2024 “Ixekizumab (IXE) is an interleukin (IL)-17A antagonist approved for the treatment of adults with moderate-to-severe psoriasis.” PMID 29116597 ↗ Dec 2017 “Ixekizumab (IXE) and ustekinumab (UST) are biologics with established efficacy in nail psoriasis.” PMID 32415575 ↗ May 2020 “Ixekizumab (IXE), an interleukin-17A inhibitor, has shown efficacy in patients with r-axSpA.” PMID 39509838 ↗ Oct 2024 “Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist” PMID 38814433 ↗ May 2024 “ixekizumab (IXE), an interleukin-17A antagonist” PMID 38332436 ↗ Feb 2024 |
| Known as | LY2439821 | “A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India” NCT05855967 ↗ |
| Known as | Taltz | “using a loading dose of 160 mg of subcutaneous ixekizumab (Taltz), followed by 80 mg of subcutaneous ixekizumab Q2 weeks for 24-weeks.” NCT06085079 ↗ |
| Action | Inhibit | “We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment.” PMID 22455413 ↗ Mar 2012 |
| Modality | Monoclonal antibody | “Ixekizumab is a monoclonal antibody that targets IL-17A, a key cytokine in psoriasis pathogenesis.” PMID 25693783 ↗ Feb 2015 |
| Route | Subcutaneous | “Patients were randomized to receive placebo, 10, 25, 75 or 150 mg of ixekizumab injected subcutaneously at weeks 0, 2, 4, 8, 12 and 16.” PMID 25693783 ↗ Feb 2015 |
| Target | IL17A | “Ixekizumab is a monoclonal antibody that targets IL-17A, a key cytokine in psoriasis pathogenesis.” PMID 25693783 ↗ Feb 2015 |